Checking out new books from the library

Exelixis Pharmaceuticals Inc.'s genomics-based discovery efforts historically have been focused on kinases. With the planned acquisition of X-Ceptor Therapeutics Inc., EXEL is branching out into nuclear hormone receptors. The company thinks it will be able to make the jump because its existing compound

Read the full 438 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE